Antisense oligonucleotides directed against human ICAM-I RNA
US5580969A · kind A · utility
17Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 12, 1993 |
| Grant date | Dec 3, 1996 |
| Priority date | — |
| Expiry date | Oct 12, 2013 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/315
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method for the treatment of septic shock and inflammatory complications of shock. A process for selectively inhibiting the expression of the human ICAM-I mRNA transcript using at least one oligonucleotide which is complementary to at least a portion of the human ICAM-I mRNA is disclosed, as are oligonucleotides which are complementary to portions of the ICAM-I mRNA and compositions comprising the oligonucleotides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.